Association of Methylenetetrahydrofolate Reductase (MTHFR) Polymorphism with Osteosarcoma in a Mexican Population.

IF 1.4 Q3 PEDIATRICS

Pediatric Reports Pub Date : 2024-09-09 DOI:10.3390/pediatric16030066

Irma G Enriquez-Maldonado, Daniel A Montes-Galindo, Rocio Ortiz-Lopez, Jesus Ojeda-Ibarra, Margarita L Martinez-Fierro, Iram P Rodriguez-Sanchez, Augusto Rojas-Martinez, Angel Zavala-Pompa, Carmen Alicia Sanchez-Ramirez, Alejandra E Hernandez-Rangel, Karmina Sanchez-Meza, Idalia Garza-Veloz, Alejandrina Rodriguez-Hernandez, Ivan Delgado-Enciso

{"title":"Association of Methylenetetrahydrofolate Reductase (MTHFR) Polymorphism with Osteosarcoma in a Mexican Population.","authors":"Irma G Enriquez-Maldonado, Daniel A Montes-Galindo, Rocio Ortiz-Lopez, Jesus Ojeda-Ibarra, Margarita L Martinez-Fierro, Iram P Rodriguez-Sanchez, Augusto Rojas-Martinez, Angel Zavala-Pompa, Carmen Alicia Sanchez-Ramirez, Alejandra E Hernandez-Rangel, Karmina Sanchez-Meza, Idalia Garza-Veloz, Alejandrina Rodriguez-Hernandez, Ivan Delgado-Enciso","doi":"10.3390/pediatric16030066","DOIUrl":null,"url":null,"abstract":"The methylenetetrahydrofolate reductase (MTHFR) gene 677C➔T polymorphism is capable of altering folate metabolism and can modify certain neoplasia risk. Reports have suggested that folate can have an influence on bone development and so it is of interest to know if the MTHFR 677C➔T polymorphism is associated with the malignant transformation process of this tissue. The polymorphism was determined in 55 patients with osteosarcoma and in 180 healthy individuals. Compared with C/T+C/C genotypes, a 3.7-fold reduction in osteosarcoma probability is possible with the T/T genotype (OR 0.27, CI 95% 0.07-0.82). Undoubtedly, further studies, utilizing large samples and carried out on different populations, are necessary to confirm these results.","PeriodicalId":45251,"journal":{"name":"Pediatric Reports","volume":"16 3","pages":"786-793"},"PeriodicalIF":1.4000,"publicationDate":"2024-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11417709/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatric Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3390/pediatric16030066","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PEDIATRICS","Score":null,"Total":0}

引用次数: 0

Abstract

The methylenetetrahydrofolate reductase (MTHFR) gene 677C➔T polymorphism is capable of altering folate metabolism and can modify certain neoplasia risk. Reports have suggested that folate can have an influence on bone development and so it is of interest to know if the MTHFR 677C➔T polymorphism is associated with the malignant transformation process of this tissue. The polymorphism was determined in 55 patients with osteosarcoma and in 180 healthy individuals. Compared with C/T+C/C genotypes, a 3.7-fold reduction in osteosarcoma probability is possible with the T/T genotype (OR 0.27, CI 95% 0.07-0.82). Undoubtedly, further studies, utilizing large samples and carried out on different populations, are necessary to confirm these results.

查看原文本刊更多论文

墨西哥人群中亚甲四氢叶酸还原酶 (MTHFR) 多态性与骨肉瘤的关系

亚甲基四氢叶酸还原酶（MTHFR）基因 677C➔T 多态性能够改变叶酸代谢，并能改变某些肿瘤的风险。有报告表明，叶酸会对骨骼发育产生影响，因此，了解 MTHFR 677C➔T 多态性是否与该组织的恶性转化过程有关很有意义。我们对 55 名骨肉瘤患者和 180 名健康人进行了多态性测定。与 C/T+C/C 基因型相比，T/T 基因型患骨肉瘤的概率降低了 3.7 倍（OR 0.27，CI 95% 0.07-0.82）。毫无疑问，要证实这些结果，还需要在不同人群中进行大样本的进一步研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pediatric Reports PEDIATRICS-

CiteScore

2.10

自引率

0.00%

发文量

审稿时长

11 weeks